Google
CRBU — CARIBOU BIOSCIENCES INC (Healthcare >> Biotechnology)
CRBU FAQ
What is CRBU's ROE?
CARIBOU BIOSCIENCES INC reports a Return on Equity (ROE) of -130.58%.
What is CRBU's dividend yield?
CARIBOU BIOSCIENCES INC offers a dividend yield of 0.00%.
What is CRBU's Deepscope Quality Score?
Deepscope rates CRBU's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CRBU?
Deepscope's AI Timing Score for CRBU is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CRBU belong to?
CARIBOU BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.92
Price
-0.15
(-7.02%)
Day Change
|
|
|---|
CRBU, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.92 |
| PBV / Sector |
1.95 / 4.63
|
| Earning Per Share | -1.29 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
4.03 M
GREAT
|
| Average 1W Daily Value |
3.98 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:21 |
| Symbol | CRBU |
| Name | CARIBOU BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 99.18 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 198.86 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2929 7th Street, Berkeley, CA, United States, 94710
Phone: 510 982 6030
Website: https://cariboubio.com
Employees: 97
Sector: Healthcare >> Biotechnology
Description: Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
